Breast cancer is the most common malignancy among women worldwide.
| INTRODUC TI ON
Breast cancer (BC) is the most common diagnosed cancer and the fifth leading cause of cancer death among women in China. 1 Although the rapid development of target therapy and immunotherapy in recent years, surgery, hormone therapy, radiotherapy and chemotherapy are still the effective options for the treatment of BC. 2 The 5-year survival rate of early-stage breast cancer (EBC) patients in China is about 58%-78%. 3 Breast cancer is a clinically heterogeneous disease. However, BC cells from the cancerous lump may have spread to other organs of patients after different kinds of treatment (a mastectomy, radiotherapy and chemotherapy). Although tumour size, histopathological grades and clinical stages are important indicators for clinical management of BC, it is a common phenomenon that histologically similar tumours may have different prognoses and respond to therapy differently, due to the molecular difference among the histologically similar tumours. Kynureninase (KYNU) or L-kynurenine hydrolase belongs to the kynureninase family. Kynureninase gene is located at 2q22. 2. 4 KYNU is a pyridoxal-5′-phosphate (pyridoxal-P)-dependent enzyme that catalyses the cleavage of L-kynurenine and L-3-hydroxykynurenine into anthranilic and 3-hydroxyanthranilic acids, respectively. Kynureninase is involved in the biosynthesis of NAD cofactors from tryptophan through the kynurenine pathway. 5 Kynureninase was associated with tryptophan utilization and metabolic diseases. It has been reported that KYNU is associated with metabolic neurological, 6 cardiac 7 and renal disease. 8 Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary cortical neurons. 9 KYNU has been reported to be down-regulated in the highly aggressive osteosarcoma cell lines. 10 The association of KYNU with cancer is rarely reported, and the role of KYNU in cancer development is unclear.
Here, we report that the expression of KYNU is negatively correlated with clinical BC histological grades and tumour stages.
Overexpression of KYNU inhibits BC cell proliferation, colony
formation and xenograft tumour development in mouse models.
Kynureninase may function as a tumour suppressor in BC. 
| MATERIAL S AND ME THODS

| Breast cancer tissue samples
| Immunohistochemistry (IHC) analysis
For IHC, briefly, 4-μm-thick paraffin-embedded tissue sections were treated with an antigen retrieval solution (eBioscience, #00-4955-58) and stained by using a Vectastain ® abc kit, according to the manufacturer's protocol (Vector Laboratories, # PK-4000). The tissue sections were incubated with the primary antibodies ( for Ki67, if ≥15% of the nuclei were stained, sample was classified as Ki67-positive (high) expression. 13 E-cad expression was considered positive if positive cells is equal to or more than 50% continuous membrane staining was present in the breast cancer cells, and negative or low expression if less than 50%, which was the median percentage observed in the included subjects. 13 The KYNU protein was found to be expressed primarily in the cytoplasm of tumour cells. The cytoplasm staining fraction (CF) was assigned a score of 0 (0%-5%), 1 (5%-25%), 2 (26%-50%), 3 (51%-75%) or 4 (>75%), and cytoplasm staining intensity (CI) was noted as 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). Subsequently, a combined Cytoplasm Score (CS) was calculated by multiplying CF and CI (range of 0-12).
TA B L E 1 Antibodies and staining conditions in the study
For statistical analyses, the cut-off values for KYNU expression were chosen on the basis of heterogeneity using the log-rank test for OS.
The optimal cut-off value was determined as low (scores ≤4) or high (scores >4) KYNU expression.
| Cells and reagents
Breast cancer MCF-7 and MDA-MB-231 cell lines were purchased from American Type Culture Collection (ATCC). They were cultured in DMEM high glucose medium supplemented with 1% HEPES, 1%
Pen/Strep, 1% sodium pyruvate and 10% foetal bovine serum (FBS) and incubated at 37°C in a humidified atmosphere containing 5%
CO2. MCF-7 and MDA-MB-231 cells stably expressing control vector (pcDNA3.1), pcDNA3.1-KYNU, were cultured in DMEM supplemented with high glucose medium supplemented with 1% HEPES, 1% Pen/strep, 1% sodium pyruvate, 10% FBS and G418 (1000 g/mL).
| Transfections
The transfection of pcDNA-KYNU (OriGene #RC214932) was performed by using the TransIT-LT1 transfection reagent (Mirus) according to manufacturer's recommendations. Stable transfection was achieved by G418 selection. For siRNA experiment, siRNAs was purchased from Santa Cruz (#sc-51370).
| Western blot analysis
Cell lysates were separated by SDS-PAGE and transferred to PVDF membranes. Immunostaining was done using antibodies specific for KYNU (GeneTex, Lot No. 33291). Chemiluminescence detection was performed by using the Pierce ECL Western blotting substrate (Thermo Scientific). 
| Cell proliferation assay
| RE SULTS
| The differential expression of KYNU in breast cancer and benign cells
Among all sections analysed, we found that KYNU protein was highly expressed both in mammary ductal carcinoma cells (Figure 1A,C) and in benign myoepithelium cells ( Figure 1D ), but not in lymphocyte and benign mammary gland luminar cells ( Figure 1C,B,D) .
The expression of KYNU was very high in well-differentiated BC cells ( Figure 1E ) and very low in poor-different BC cells ( Figure 1F ).
| The expression of KYNU is positively correlated with BC differentiation but negatively with BC tumour grade and tumour stage
As shown in Figure 2 , KYNU was highly expressed in well-differentiated BC (Grade I) ( Figure 2A ) while its expression was medium in middle-differentiated BC (Grade II) ( Figure 2B) and very low or lost in poor-differentiated BC (Grade III) ( Figure 2C ). The expression of KYNU was negatively correlated with the histopathological grades of BC ( Figure 2H) . Similarly, the expression of KYNU was very high Figure 2D ), high in T1 BC (Figure 2E ), while its expression was low in T2 BC ( Figure 2F ) and very low in T3 BC ( Figure 2G ). The expression of KYNU was reversely related to tumour stage (T stage) ( Figure 2I ).
| The association of KYNU expression with breast cancer clinicopathological characteristics
Typical clinicopathological parameters and immunohistochemical staining of low or high KYNU expression are shown in Table 2 .
Among 137 primary BC tissues, 46.7% (64/137) had high KYNU expression (IHC scores >4), while 53.3% (73/137) showed low KYNU expression (IHC scores ≤4). As summarized in Table 2 , the expression of KYNU was positively associated with the expression of ER (P = .002), PR (P = .007) and E-cad (P = .03), while it was negatively related to the expressions of HER2 (P = .04) and Ki-67 (P = .019).
However, the expression of KYNU was not significantly related to patients' age (year) or N-stage(N) of BC.
| The association of KYNU expression with other biomarkers of BC
We further analysed the correlation of KYNU expression with expression of other biomarkers. We found that the expression of KYNU was positively associated with the expression of ER, PR and E-cadherin (Table 2, Figure 3A -C), respectively, while negatively related to the expression of HER2 (Table 2, Figure 4D ) and Ki-67 (Table 2, Figure 3E ).
| Overexpression of KYNU inhibits BC proliferation in culture and colony formation in soft agar
To investigate the role of KYNU in BC development, we established stable KYNU overexpression BC cell lines by transfecting MCF7 and MDA-MB-23l cells with KYNU expression plasmid. Several clones with stable KYNU overexpression in each cell type were obtained ( Figure 4A,B) . MTT assays showed that KYNU overexpression MCF7 or MDA-MB-231 cells proliferated significantly slower than control cells ( Figure 4C,D) . Soft agar colony formation assay showed that KYNU overexpression MCF7 or MDA-MB-231 cells had significantly fewer colony formation than control cells ( Figure 4E ). Figure 5A ). We found that tumour weight was significantly higher in control mice than in KYNU-OE mice ( Figure 5B ).
| KYNU suppresses BC xenograft tumour development in mouse models
MDA-MB-231 cells with overexpression of KYNU had significant slower tumour development in mice than control cells ( Figure 5A,B ), suggesting overexpression of KYNU inhibits BC development.
| D ISCUSS I ON
Breast cancer (BC) is the most common cancer in females and the leading cause of death worldwide, 14 which are clinically heterogeneous. Because of heterogeneous, clinically BC may be respond poorly to neoadjuvant chemotherapy, or it is respond well to endocrine therapy. 15 After a loss or reduction of the suppressor genes in its function, normal cells may become into cancer cells with the combination of other genetic changes. 16 Scientists have learned more about the molecular changes that lead to cancer. The loss of these suppressor genes may be even more important than protooncogene/oncogene activation for the formation of many kinds of human cancer cells. 17 in regulating invasion and local dissemination. 19 Time-lapse microscopy revealed that myoepithelial cells collectively restrain and reinternalize invading Twist1+luminal cells. 19 Barrier function correlated with myoepithelial abundance and required the expression of αsmooth muscle actin and P-cadherin. 19 The data showed the concept of the myoepithelium as a dynamic barrier to luminal dissemination Here, we report that the expression of KYNU is negatively correlated with clinical BC histological grades and tumour stages.
Overexpression of KYNU inhibits BC cell proliferation, colony formation and xenograft tumour development in mouse models.
What do we know, it is not reported that KYNU is related to human breast cancer. Our data showed that KYNU may function as a tumour suppressor in BC. Therefore, KYNU is a promising therapeutic target of BC, but it need take a more further study of KYNU. Here, we only had a try for a Sea horse test ( Figure S1 ). In the future, we will study more about the KYNU molecular changes that lead to breast cancer.
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